Prof Elena Baranova MD PhD
*European Expert “Genomics for Health”for the European Commission, EU.
President of the European Instritute of Personalised Prevention, Nice, France.
** International Expert for Human Genetics. Chief of the Laboratory of Inherited Diseases and Prenatal Diagnostics (Russian Academy of Sciences), St.Petersbourg, Russia
Highest French University DiplomaHabilitation à Diriger des Recherches (HDR) Cellular & Molecular Genetics (France)
(Spécialisation : New genetics –pharmacogenomics, nutrigenetics, etc..) 1999
PhD : Cellular & Molecular Genetics (polymorphic effects of metabolic genes. Practical applications)
(France) 1999 Diploma in Genetic Epidemiology
European Mediterranean School of Medical Statistics and Clinical Epidemiology.
(Harvard University Program) 1999Diploma in Clinical Epidemiology European Mediterranean School of Medical Statistics and Clinical Epidemiology
(Harvard University Program) 1998Specialisation in infectious diseases (St.Peterburg, Russia) 1992 MD (St Petersburg, Russia) 1990Diploma in biocybernetic medicine & GDV techniques 2005Training in psychosomatic disorders & strategic therapy 2000-2002 PROFESSIONALPresident of the European Institute of Personalised Prevention since March 2005European Expert for Project Evaluation
Genomics, Life Sciences, Biotechnology for Health
Sixth EU Framework Programme since December 2003
(expert number: EX2002B003566)
Participation in project evaluation and determination of the European strategies
for “Food safety & quality” (priority 5) and Marie-Curie Actions.
Consultant-expert in Genomics for Health & Biotechnology since 2002
“Gènes-Environnement” – Clermont-Ferrand/ Paris – France.
Counselling in setting & development of projects in molecular biology, October
new genetics and personalised medicine/prevention / anti-aging fields.
Expertises for result interpretation of genetic tests
2007 - New Look on Anti-Ageing Medicine through Genomics and Evidence Based Medicine. What Can Be Done in Practice.
The beginning of postgenomic era after finalisation of the International Human Genome Project (2003) and integration of the genetic knowledge in everyday life provoke the revolutionary changes in our society from medical, social and psychological points of view. It is a tremendous source of new opportunities and positive practical applications, which should be, however, correctly applied. It especially concerns anti-aging medicine, which represents an important potential for genomics use in relation to early presymptomatic prevention through effective genetic personalized programs.
This presentation highlights principle differences in the vision of longevity and anti-aging processes from genetic and evidence based medicine point of view. The analysis of aging processes in different organs and tissues according to gene regulation and their further clinical impact is discussed and key routinely used genetic markers are demonstrated.
Main international strategies in this area are presented and include:
- In relation to longevity: ECNIS and Environmental Genome Project (EGP), which study main environment-gene interactions and key markers for polygenic multifactorial diseases and conditions (diabetes type II, cardiovascular risk, allergies, cancer, aging processes, etc..). These markers, therefore, represent the major genetic source for the development of personalized prevention.
- In relation to anti-aging: GEHA - Genetics of Healthy Aging . The project regroups 11 different countries and studies gene regulation processes during health aging.
The following questions will be also highlighted:
1. Aging and longevity – 2 sides of the coin from genetic point of view:
- longevity genes
- aging/ anti-aging genes and processes
2. Vital necessity and practical application of evidence based medicine in genomics and anti-aging. Why and How?
3. Development of practical genetic programmes for anti-aging medicine.
Special attention will be given for different European Strategies for genomics and prevention development, including education of physicians.